Shares of personal wellness company WeightWatchers (NASDAQ:WW) jumped 132% in the afternoon session after the company announced plans to make it easier for its members to access Eli Lilly's FDA-approved weight loss drug Zepbound. Given the success of weight loss drugs with regulatory approval and the crackdown on knock-offs, expanding the distribution of Zepbound should accelerate adoption. Additionally, companies such as WeightWatchers should benefit from increased sales volume and greater customer loyalty as they align themselves with medically endorsed treatments.
Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO)
fell 34.8% in the afternoon session after the company reported disappointing first-quarter 2025 earnings as sales fell below Wall Street's expectations. Another blemish was that while full-year revenue guidance was raised, full-year EBITDA guidance was maintained, signaling that profit margins for the year would be lower than initially expected. On the other hand, NeoGenomics beat analysts' EPS expectations, and its full-year revenue guidance exceeded Wall Street's estimates. Overall, this quarter was mixed. The areas below expectations seemed to be driving the move.
Wall Street divided on dollar's future. Wells Fargo bullish, Goldman Sachs bearish. Dollar hit high short positions, oversold, due to US policy uncertainty.
Faraday Future has seen its stock climb 50% over the past week. The California-based electric vehicle maker recently appointed founder YT Jia as Co-CEO.
Sherwin-Williams Co (NYSE:SHW) reported first-quarter financial results before the market open on Tuesday. Here's a look at the key metrics from the quarter.
